NIAID Funding News, January 21, 2021

January 21, 2021 NIAID Funding News Read this full edition online at http://www.niaid.nih.gov/grants-contracts/funding-news-notices Feature Articles  Writing a Winning Application—Consider the Review Committee Match your research project to a review group with appropriate expertise and create an application that appeals to the reviewers by proposing concepts and preliminary data they would regard as innovative. Opportunities and Resources Opportunity for Early-Stage Investigators To Shift Research Direction Through a new funding opportunity announcement, NIAID will fund innovative projects that represent a change of research direction for early-stage investigators and for which preliminary data do not exist.  Help Address Vaccine Hesitancy and Uptake Among Populations Experiencing Health Disparities Apply for research funding to use scientific methods to address vaccine hesitancy, uptake, and implementation among groups experiencing health disparities. Contract Funds for Clinical Pharmacology Quality Assurance The request for proposals seeks an offeror capable of providing quality assessment for pharmacology labs that test samples from NIAID-supported clinical studies. NIAID Solicitation Invites Proposals for Early-Phase Clinical Trial Units NIAID seeks offerors capable of implementing Phase 0 to Phase II clinical trials, including proof-of-concept studies, in healthy and diseased human populations—domestically and internationally—in an expeditious and efficient manner. In The News Submit Collaborative Proposals for Infectious Disease and Immunology Research Awards Submit a proposal centered on questions directly related to the Asia-Pacific region with potential to add to global knowledge about infectious diseases and immunology. Change of Platform for Federal Financial Report Submissions Effective immediately, grantees must submit Federal Financial Reports through the Payment Management System rather than the eRA Commons module previously used. Plan Ahead for October Meeting on Pulmonary Chemical Injuries The meeting will focus on topics like emerging science in pathology, pharmacology, and therapeutics for acute lung injury, acute respiratory distress syndrome, interstitial lung disease, and pulmonary fibrosis. Advice Corner Ask Permission, Not Forgiveness, for a Change in Scope Before implementing a change in scope, you need to request and receive NIAID's written prior approval. We highly encourage you to discuss the possibility with the assigned program officer before submitting the request. Reader Questions "I am eligible for continuous submission. What is my next submission deadline for an AIDS-related R01 grant application?" "When it comes to applying for NIH grants and scholarships, who qualifies as an underrepresented person?" New Funding Opportunities PAR-21-082, NIAID SBIR Phase II Clinical Trial Implementation Cooperative Agreement (U44, Clinical Trial Required) PAR-21-083, NIAID Clinical Trial Implementation Cooperative Agreement (U01, Clinical Trial Required) RFA-AI-20-078, Immune Development in Early Life (IDEaL) (U19, Clinical Trial Not Allowed) RFA-AI-20-077, Immune Development in Early Life (IDEaL) (U01, Clinical Trial Not Allowed) Clinical Pharmacology Quality Assurance (CPQA) Program RFA-AI-21-001, Tuberculosis Research Advancement Centers (P30, Clinical Trials Not Allowed) NOT-MD-21-008, Notice of Special Interest (NOSI)—Research To Address Vaccine Hesitancy, Uptake, and Implementation Among Populations That Experience Health Disparities Find other announcements at NIAID Opportunities & Announcements. Send suggestions or comments to deaweb@niaid.nih.gov. National Institute of Allergy and Infectious Diseases  |  National Institutes of Health Update your subscriptions, modify your password or e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact Subscriber Help. This service is provided to you at no charge by National Institute of Allergy and Infectious Diseases (NIAID).                             This email was sent to edwardlorilla1986.paxforex@blogger.com using GovDelivery Communications Cloud on behalf of: National Institute of Allergy and Infectious Diseases · 5601 Fishers Lane · Bethesda, MD 20892 · 1-866-284-4107